Scott Thacher

Company: Orphagen Pharmaceuticals

Job title: CEO and Founder

Seminars:

A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells 2:30 pm

Antagonists to retinoic acid receptor-alpha (RARα) block upregulation of α4β7 and CCR9 during T cell activation in mesenteric lymph nodes Inflammatory damage to mucosal epithelia is significantly inhibited in colitis and related disease models by concomitant daily oral dosing of an RARα antagonist Preclinical safety findings for the highly selective RARα antagonist OR-812 support further…Read more

day: Day One